New drug for Pulmonary Arterial Hypertension now available in Alberta
-
Share on Facebook
-
Share on Bluesky
-
Share on X
- Copy Link
A new treatment for the rare disease known as pulmonary arterial hypertension (PAH) is now available in Alberta.
The provincial government shared Friday that patients will now be covered through the Specialized High Cost Drug Program for the drug Sotatercept.
According to a release, pulmonary arterial hypertension is a rare but devastating condition that causes high blood pressure in the lungs. Over time, it places stress on the right side of the heart and can lead to heart failure. It is progressive, disabling and life-threatening with no cure.
“As both a pulmonary hypertension physician in Alberta and a board director at the Pulmonary Hypertension Association of Canada, I am incredibly happy and thankful that Sotatercept is now available to Albertans,” says Dr. Mitesh Thakrar, physician, Peter Lougheed Center, and board director, Pulmonary Hypertension Association Canada.
